Today: 11 June 2026
Salesforce stock today: CRM ticks up as Fed minutes loom in thin year-end trade
30 December 2025
2 mins read

Salesforce stock today: CRM ticks up as Fed minutes loom in thin year-end trade

NEW YORK, December 30, 2025, 12:06 ET — Regular session

  • Salesforce shares were up about 0.2% at $266.84 in midday trading.
  • Investors are watching Fed meeting minutes due at 2 p.m. ET, a potential catalyst for rate-sensitive tech stocks.
  • Enterprise software peers were mixed, with Oracle higher and ServiceNow slightly lower.

Salesforce (NYSE:CRM) shares inched higher on Tuesday as investors positioned ahead of U.S. Federal Reserve minutes due later in the day. The stock was up about 0.2% at $266.84 in midday trading.

The Fed release matters now because interest-rate expectations can quickly reset valuations for growth stocks, including subscription-based software companies. Investors often use the minutes to gauge whether policymakers are leaning toward more rate cuts or a longer pause.

Trading was thin heading into year-end, with U.S. markets set to close on Thursday for New Year’s Day, Reuters reported. “I wouldn’t try to make too much out of anything that happens in a holiday-shortened week,” said Art Hogan, chief market strategist at B Riley Wealth. Reuters

Broader equity moves were muted, with some large-cap technology names under renewed pressure, Reuters said, after gains in the sector helped push the S&P 500 to record highs last week.

Salesforce’s move broadly tracked other enterprise-software shares. ServiceNow slipped about 0.2%, while Microsoft rose about 0.2% and Oracle climbed roughly 1.1%.

Company-specific headlines were limited, leaving investors focused on the next readout on Salesforce’s AI push. On Dec. 3, Salesforce raised its fiscal 2026 revenue and adjusted profit forecasts, pointing to stronger adoption of its Agentforce platform, Reuters reported.

Agentforce is built around “AI agents” — software designed to take actions on a user’s behalf, such as handling routine sales or service tasks. Salesforce has pitched faster take-up of those tools as a driver of recurring subscription revenue. Reuters+1

Salesforce said its Agentforce and Data 360 products were generating about $1.4 billion in annual recurring revenue, a metric that estimates subscription revenue over the next 12 months, Reuters reported. Investors have been looking for signs those products can scale without squeezing margins.

Another focus is execution after Salesforce said it completed its acquisition of data-management firm Informatica on Nov. 18. The company has framed the deal as strengthening the data foundation that helps AI tools work across customer systems.

The Fed is set to publish minutes from its Dec. 9-10 meeting at 2 p.m. ET, according to the central bank’s calendar. The meeting ended with a 25-basis-point cut — a quarter of a percentage point — and several dissents, Reuters reported.

Traders will read the minutes for clues on how high the bar is for additional cuts in 2026. Shifts in the rate outlook can move Treasury yields and spill over into software shares that investors often treat as long-duration bets on future earnings.

Salesforce traded between $265.38 and $268.21 earlier Tuesday. Beyond the Fed minutes, investors will keep a close eye on updates on Agentforce demand and profitability as the company moves toward its next quarterly results.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers
Previous Story

AMD stock today: Shares tick higher after hours as year-end tech selling weighs on chipmakers

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake
Next Story

Nvidia stock dips after AI21 Labs talk report as NVDA investors size up Intel stake

Go toTop